Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

Overview of attention for article published in Journal of Hematology & Oncology, August 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#14 of 1,284)
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news: 29 news outlets
twitter: 2 X users

wikipedia: 1 Wikipedia page

Citations

dimensions_citation: 28 Dimensions

Readers on

mendeley: 27 Mendeley

Summary News X Wikipedia Dimensions citations

So far, Dimensions has found 28 publications that cite this research output.

28

The most recent citing publications are shown below. View all 28 publications that cite this research output on Dimensions.

Ponatinib‐review of historical development, current status, and future research

Article in American Journal of Hematology (May 2024)

A safety review of tyrosine kinase inhibitors for chronic myeloid leukemia

Article in Expert Opinion on Drug Safety (April 2024)

Chronic myeloid leukaemia: Biology and therapy

Article in Blood Reviews (March 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.